Literature DB >> 2659110

Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry.

K Atkinson1, M M Horowitz, R P Gale, M B Lee, A A Rimm, M M Bortin.   

Abstract

A questionnaire comprised of a series of clinical vignettes illustrating potential difficulties in diagnosis, grading and treatment of chronic graft-versus-host disease (GVHD) was completed by 65 bone marrow transplant physicians from 51 transplant centers worldwide. The concordance index (CI) for responses to each question was calculated using the formula CI = 2p-1, where p was the percentage agreement among respondents. Possible responses ranged from 0 (no agreement) to 1.00 (perfect agreement). Responses indicated moderate (CI = 0.55), high (CI = 0.88) and moderate (CI = 0.54) agreement among transplanters for diagnosis, grading and treatment of chronic GVHD, respectively. Disagreement was observed in (1) diagnosis of uncommon manifestations of chronic GVHD; (2) in interpretation of symptoms which occur less than 2 months after transplant; (3) in interpretation of persistent stable symptoms; and (4) in deciding whether to treat chronic GVHD limited to skin. The results point to potential problem areas in designing and interpreting clinical trials to prevent or treat chronic GVHD and highlight the need for improved diagnostic criteria.

Entities:  

Mesh:

Year:  1989        PMID: 2659110

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  27 in total

1.  Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.

Authors:  Nancy M Hardy; Miriam E Mossoba; Seth M Steinberg; Vicki Fellowes; Xiao-Yi Yan; Frances T Hakim; Rebecca R Babb; Daniele Avila; Juan Gea-Banacloche; Claude Sportès; Bruce L Levine; Carl H June; Hahn M Khuu; Ashley E Carpenter; Michael C Krumlauf; Andrew J Dwyer; Ronald E Gress; Daniel H Fowler; Michael R Bishop
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

2.  Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.

Authors:  K Mallhi; P J Orchard; W P Miller; Q Cao; J Tolar; T C Lund
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

3.  Related and unrelated donor transplantation for β-thalassemia major: results of an international survey.

Authors:  Chunfu Li; Vikram Mathews; Soyoung Kim; Biju George; Kyle Hebert; Hua Jiang; Changgang Li; Yiping Zhu; Daniel A Keesler; Jaap Jan Boelens; Christopher C Dvorak; Rajni Agarwal; Jeffery J Auletta; Rakesh K Goyal; Rabi Hanna; Kimberly Kasow; Shalini Shenoy; Angela R Smith; Mark C Walters; Mary Eapen
Journal:  Blood Adv       Date:  2019-09-10

4.  Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Authors:  Claudio G Brunstein; Effie W Petersdorf; Todd E DeFor; Harriet Noreen; David Maurer; Margaret L MacMillan; Celalettin Ustun; Michael R Verneris; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-30       Impact factor: 5.742

5.  Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Authors:  Nelli Bejanyan; Soyoung Kim; Kyle M Hebert; Natasha Kekre; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Sherif M Badawy; Amer Beitinjaneh; Jaap Jan Boelens; Miguel Angel Diaz; Christopher C Dvorak; Shahinaz Gadalla; James Gajewski; Robert Peter Gale; Siddhartha Ganguly; Andrew R Gennery; Biju George; Usama Gergis; David Gómez-Almaguer; Marta Gonzalez Vicent; Hasan Hashem; Rammurti T Kamble; Kimberly A Kasow; Hillard M Lazarus; Vikram Mathews; Paul J Orchard; Michael Pulsipher; Olle Ringden; Kirk Schultz; Pierre Teira; Ann E Woolfrey; Blachy Dávila Saldaña; Bipin Savani; Jacek Winiarski; Jean Yared; Daniel J Weisdorf; Joseph H Antin; Mary Eapen
Journal:  Blood Adv       Date:  2019-10-22

6.  In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.

Authors:  Sherif S Farag; Shivani Srivastava; Steven Messina-Graham; Jennifer Schwartz; Michael J Robertson; Rafat Abonour; Kenneth Cornetta; Lisa Wood; Angie Secrest; R Matthew Strother; David R Jones; Hal E Broxmeyer
Journal:  Stem Cells Dev       Date:  2013-02-15       Impact factor: 3.272

Review 7.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Authors:  J Schetelig; M Schaich; K Schäfer-Eckart; M Hänel; W E Aulitzky; H Einsele; N Schmitz; W Rösler; M Stelljes; C D Baldus; A D Ho; A Neubauer; H Serve; J Mayer; W E Berdel; B Mohr; U Oelschlägel; S Parmentier; C Röllig; M Kramer; U Platzbecker; T Illmer; C Thiede; M Bornhäuser; G Ehninger
Journal:  Leukemia       Date:  2014-12-01       Impact factor: 11.528

9.  Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.

Authors:  M Al-Mofareh; M Ayas; A Al-Seraihy; K Siddiqui; A Al-Jefri; I Ghemlas; H Alsaedi; H El-Solh; S Al-Sweedan; B Al-Saud; H Al-Mousa; H Al-Dhekri; R Arnaout; R Mohammed; S Al-Muhsen; A Al-Ahmari
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

10.  Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.

Authors:  Merav Bar; Brenda M Sandmaier; Yoshihiro Inamoto; Benedetto Bruno; Parameswaran Hari; Thomas Chauncey; Paul J Martin; Rainer Storb; David G Maloney; Barry Storer; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.